Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab observational study in malignant solid tumors
ChiCTR2000031938Phase 4Recruiting
- Sponsor
- Xi'an Jiaotong University
- Start
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in Non-hematologic malignancy, sponsored by Xi'an Jiaotong University. Primary endpoints: Progression-free survival and Quality of life. Started Apr 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2000031938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031938.